Biopharma – Talk Bio

Biopharma Layoff Trends in Q1 2025 and Outlook for Q2

2 weeks ago talkbio0Tagged Biopharma, Biopharma layoffs, Changing, Industry, Legal patent, Pharma, pharmaceutical employment, Q1 2025, Q2 layoff, regulatory, restructuring

Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.

BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease

2 months ago talkbio0Tagged BioCity, Biopharma, Diabetic Nephropathy, EDNRA gene, ETA, Phase 2 trial, Proteinuria, SC0062

SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

2 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

3 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

3 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement

Empowering Women’s Health: First Lady Jill Biden and Biopharma Leaders Unite at JPM25

3 months ago talkbio0Tagged Biopharma, first, Health care facility, J.P. Morgan, Jill Biden, JPM25, women 's health

JPM25, Women’s Health, First Lady Jill Biden, Biopharma, Healthcare Investment, J.P. Morgan Healthcare Conference

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

3 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference

3 months ago talkbio0Tagged Acquisitions, Biopharma, Eli, Eli Lilly, Industry, J.P. Morgan Healthcare, JPM25, partnerships, Pharma, Scorpions, SmithKline Beecham, Zealand

JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees

4 months ago talkbio0Tagged 2024, Advocacy, Biopharma, Fierce, Health Equity, healthcare innovation, honorees

Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy